TABLE 3.
HIV+subjects (n = 39) | Non-HIV healthycontrols (n = 13) | Non-HIV unhealthycontrols2 (n = 18) | Bonferroni-adjusted P values |
||||
Characteristic | OverallP value3 | 1 vs 3 | 1 vs 2 | 2 vs 3 | |||
14:0 (%nmol) | 1.0 ± 3.14 | 0.6 ± 0.1 | 0.6 ± 0.2 | 0.71 | — | — | — |
16:0 (%nmol) | 29.0 ± 2.7 | 36.5 ± 3.6 | 34.4 ± 2.7 | <0.001 | <0.001 | <0.001 | 0.21 |
16:1n−7 (%nmol) | 0.7 ± 0.3 | 0.4 ± 0.2 | 0.7 ± 0.4 | 0.011 | 0.99 | <0.001 | 0.009 |
18:0 (%nmol) | 14.7 ± 2.1 | 9.7 ± 2.1 | 12.0 ± 1.8 | <0.001 | <0.001 | <0.001 | 0.003 |
18:1n−9 (%nmol) | 12.7 ± 2.5 | 13.5 ± 1.7 | 13.2 ± 2.4 | 0.41 | — | — | — |
18:2n−6 (%nmol) | 21.3 ± 3.1 | 24.1 ± 4.7 | 25.0 ± 4.1 | 0.003 | 0.001 | 0.12 | 0.99 |
18:3n−3 (%nmol) | 0.26 ± 0.15 | 0.02 ± 0.04 | 0.04 ± 0.09 | <0.001 | <0.001 | <0.001 | 0.99 |
20:3n−9 (%nmol) | 0.26 ± 0.16 | 0.00 ± 0.00 | 0.03 ± 0.09 | <0.001 | <0.001 | <0.001 | 0.60 |
20:3n−6 (%nmol) | 3.9 ± 1.4 | 1.8 ± 1.3 | 1.1 ± 1.1 | <0.001 | <0.001 | <0.001 | 0.30 |
20:4n−6 (%nmol) | 11.5 ± 2.7 | 11.3 ± 2.1 | 10.8 ± 2.9 | 0.61 | — | — | — |
20:5n−3 (%nmol) | 0.8 ± 0.7 | 0.2 ± 0.6 | 0.2 ± 0.3 | <0.001 | <0.001 | 0.012 | 0.99 |
22:4n−6 (%nmol) | 0.37 ± 0.17 | 0.13 ± 0.12 | 0.12 ± 0.12 | <0.001 | <0.001 | <0.001 | 0.99 |
22:5n−6 (%nmol) | 0.32 ± 0.15 | 0.05 ± 0.09 | 0.04 ± 0.07 | <0.001 | <0.001 | <0.001 | 0.99 |
22:5n−3 (%nmol) | 0.7 ± 0.4 | 0.1 ± 0.1 | 0.2 ± 0.1 | <0.001 | <0.001 | <0.001 | 0.40 |
22:6n−3 (%nmol) | 2.5 ± 0.9 | 1.7 ± 0.9 | 1.6 ± 1.0 | 0.002 | 0.0021 | 0.015 | 0.99 |
Total 20:5n−3 + 22:6n−3 (%nmol) | 3.3 ± 1.2 | 1.9 ± 1.0 | 1.8 ± 1.2 | <0.001 | <0.001 | <0.001 | 0.99 |
Total SFAs (%nmol) | 44.8 ± 3.1 | 46.8 ± 2.2 | 47.1 ± 2.6 | 0.010 | 0.012 | 0.03 | 0.99 |
Total MUFAs (%nmol) | 13.4 ± 2.7 | 13.9 ± 1.7 | 13.9 ± 2.6 | 0.65 | — | — | — |
Total PUFAs (%nmol) | 41.8 ± 2.6 | 39.3 ± 3.0 | 39.0 ± 2.7 | <0.001 | 0.003 | 0.018 | 0.99 |
n−6 (%nmol) | 37.4 ± 2.4 | 37.3 ± 3.0 | 37.0 ± 3.2 | 0.92 | — | — | — |
n−3 (%nmol) | 4.2 ± 1.4 | 2.1 ± 1.1 | 2.0 ± 1.3 | <0.001 | <0.001 | <0.001 | 0.99 |
n−6/n−3 Ratio | 9.8 ± 3.1 | 20.7 ± 11.8 | 25.5 ± 21.0 | <0.001 | 0.006 | 0.003 | 0.99 |
20:3n−9/20:4n−6 Ratio | 0.03 ± 0.1 | 0.00 ± 0.00 | 0.00 ± 0.01 | <0.001 | <0.001 | <0.001 | 0.54 |
Total PLs (nmol/mL) | 5583 ± 1420 | 2729 ± 615 | 3072 ± 843 | <0.001 | <0.001 | <0.001 | 0.54 |
Total TGs (nmol/mL) | 8669 ± 5716 | 2726 ± 905 | 4186 ± 2066 | <0.001 | <0.001 | <0.001 | 0.027 |
SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; PLs, phospholipids; TGs, triglycerides.
Non-HIV unhealthy controls had elevated serum triglycerides (>150 mg/dL) and/or insulin resistance.
Overall P values are from type 3 score statistics for continuous variables and chi-square test for categorical variables.
Mean ± SD (all such values).